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T-cell receptor (TCR) immunotherapy uses T cells engineered with new TCRs to enable detection and
killing of cancer cells. Efficacy of TCR immunotherapy depends on targeting antigenic peptides that are
efficiently presented by the best-suited major histocompatibility complex (MHC) molecules of cancer cells.
However, efficient strategies are lacking to easily identify TCRs recognizing immunodominant peptide-
MHC (pMHC) combinations utilizing any of the six possible MHC class I alleles of a cancer cell. We
generated an MHC cell library and developed a platform approach to detect, isolate, and re-express TCRs
specific for immunodominant pMHCs. The platform approach was applied to identify a human papillo-
mavirus (HPV16) oncogene E5-specific TCR, recognizing a novel, naturally processed pMHC (HLA-
B*15:01) and a cytomegalovirus-specific TCR targeting an immunodominant pMHC (HLA-B*07:02). The
platform provides a useful tool to isolate in an unbiased manner TCRs specific for novel and im-
munodominant pMHC targets for use in TCR immunotherapy.
Keywords: immunotherapy, T cell receptor (TCR) discovery, TCR gene therapy, MHC cell library,
immunodominance, human papillomavirus ES
INTRODUCTION
ADOPTIVE TRANSFER OF receptor-engineered T cells
has shown remarkable response rates in clinical
trials of end-stage treatment-refractory leukemia
patients, demonstrating the potential of thera-
peutic T cells to eradicate tumor cells.1,2 In most
studies, T cells were engineered with a chimeric
antigen receptor (CAR) to provide a new antigen
specificity. Due to their antibody-like nature, CARs
only bind surface antigens expressed by target
cells. In contrast, T-cell receptor (TCR)-based rec-
ognition of target cells involves three components:
the TCR, the antigenic peptide (epitope), and one
MHC (i.e., HLA-A*02:01) molecule that presents
the epitope at the cell surface. Compared to CARs,
TCRs have the major advantage that they can
target intracellular and mutated antigens that
are endogenously expressed, processed, and fi-
nally presented on MHCmolecules. Furthermore,
non-malignant stroma cells in the tumor micro-
environment may also take up antigen released
from dying tumor cells and present tumor epitopes
on their cell surfaces. Thereby, stroma cells become
susceptible to TCR-based T-cell attack. Targeting
the tumor microenvironment is an important fea-
ture of successful T-cell therapy that can be lever-
aged using TCRs to treat solid tumors.3–5
A crucial aspect for the outcome of TCR immu-
notherapy is the identification of TCRs that target
peptide-MHC (pMHC) combinations efficiently ex-
pressed by cancer cells. Historically, TCR studies
have focused primarily on the most frequent MHC
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allele HLA-A*02:01, which, depending on the pa-
tient population, is expressed by 18–47% of indi-
viduals.6 TCRs restricted to HLA-A*02:01 are
thereby applicable to only a limited number of pa-
tients. However, as antigens are expressed and
degraded by the antigen-processing machinery of a
cell, epitopes are generated that may fit into the
binding groove of any of the six possible MHC class
I alleles of the cell. Currently, available software
algorithms fail to predict accurately which pMHC
combinations are most efficiently presented at
the cell surface to engage TCRs and induce strong
T-cell responses. Therefore, strategies are required
to enable unbiased identification of immunodomi-
nant pMHC combinations, taking into account all
MHC alleles of a given donor.
For endogenous processing and presentation
of pMHCs, we focused on two antigen-presenting
cell (APC) types that have the capacity to stimulate
T-cell responses.7,8 Professional APCs (pAPC) induce
the most potent T-cell responses. Expression of im-
muneproteasomes isakey featureenablingpAPCs to
increasetheirability togenerateepitopesandexpress
cell surface pMHCs as targets for TCRs. Simulta-
neously, the accessory molecules CD80 and CD86
bind to CD28 on T cells, providing critical co-
stimulatory signals. Mature dendritic cells (mDC)
are potent pAPC to enrich antigen-specific T cells
in vitro.9,10 The human erythroleukemic cell line
K562canalsobeusedasAPC. It lacksnatural surface
expression of MHC I and MHC II alleles but does
express b-2 microglobulin.11 Thus, upon transgenic
expression of an MHC allele, such as the HLA-
A*02:01 alpha chain, these cells acquire functional
antigen-processing andpresentation capacity to form
cell surface pMHCs.12–15 Such MHC-engineered
K562 cells can form immunological synapses due to
their co-expression of ICAM-1 and LFA-3 through
which T cells can be activated.15 Importantly, K562
cells do not contain viral sequences,16 which could
lead to unwanted responses, and express constitutive
proteasomes that provide antigen processing typical
of tumor cells.17
This study used a multi-step platform ap-
proach for the identification, isolation, and char-
acterization of TCRs using DC-based enrichment
of antigen-specific T cells combined with the ap-
plication of a K562-based MHC cell library. Using
this platform, we identified a TCR specific for a
novel human papillomavirus HPV16 E5 epitope
presented by HLA-B*15:01 and a TCR specific for
a human cytomegalovirus (CMV) pp65 epitope
presented by HLA-B*07:02. Both TCRs may
be candidates for clinical application of TCR
immunotherapy.
METHODS
In silico analysis of epitopes
To determine epitopes that have the highest
binding affinity to a givenMHC class Imolecule, the
online prediction server netMHCpan3.0 was used
(www.cbs.dtu.dk/services/NetMHCpan/) employing
artificial neural networks (ANNs).18 Queries of the
HPV16 E5 and CMV pp65 reference protein se-
quences were made to return 9-mer and 10-mer
peptides for the six HLA alleles of the donor. Bind-
ing prediction is calculated based on 180.000 quan-
titative binding data. Strong binding of an epitope to
the HLA is indicated by a percentage rank of <0.5
among all epitopes from the database.Weak binders
are indicated by a percentage rank of <2.0. The
Expitope server (http://webclu.bio.wzw.tum.de/
expitope/) enables the search for epitopes from the
human proteome, which may be targets of cross-
reactivity for TCRs.19 According to results of the al-
anine scan, the SafRCFivY epitope ofHPV16E5was
submitted to determine sequence-similar epitopes
that may be expressed in healthy tissues and could
potentially be recognized by the E5-specific TCR.
Lowercase letters in the epitope sequence represent
non-fixed positions of the epitope. Expitope analyzes
RNA-seq expression databases and further returns a
combined prediction score for proteasomal cleavage,
TAP transporter, and MHC binding affinity to indi-
cate the probability of sequence-similar epitopes to
be targets of cross-reactivity.
Cell lines
Suspension cells (lymphoblastoid cell lines [LCLs],
K562) were cultured in RPMI1640 medium (Gibco)
supplemented with 10% fetal bovine serum (FBS;
Pan Biotech), 1·minimum essential medium non-
essential amino acids, 1· sodium pyruvate, 1·pen-
icillin/streptomycin (all Gibco). LCLs (obtained from
the International Histocompatibility Work Group)
were seeded at 0.5·106/mL, and passaging was
performed at a ratio of 1:2. K562 cells (ATCC CCL-
243) were seeded at 0.1·106/mL and split twice a
week at 1:5 to 1:20. Adherent HPV16-positive cervi-
cal carcinoma-derived cell lines CaSki (ATCC CRL-
1550) and SiHa (ATCCHTB-35) andHPV16-positive
head and neck cancer cell lines SCC090 and SCC152
(LGC Standards) were seeded at 1–2 · 106 cells/
75 cm2 cell culture flask in 15mL of Dulbecco’s
modified Eagle’s medium (DMEM)-Ham’s F12
(Gibco) supplemented with 10% FBS and 1x peni-
cillin/streptomycin. Cells were split using 0.125%
trypsin-EDTA (Gibco). The HG820-GALV packag-
ing cell line (Eufets)20 was cultured at 1–2·106
cells/75 cm2 flask in DMEM (Gibco) supplemented
with 10% FBS and 1·penicillin/streptomycin.
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Generation of antigen-expressing DCs
and stimulation of T cells
HPV16 E5- and CMV pp65-encoding genes were
molecularly cloned into the expression plasmid
pcDNA3.1(–) (Invitrogen) under the control of a T7
promoter. Plasmids were linearized by restriction
enzyme digestion at the 3¢ end of the transgene.
ivtRNA was generated using in vitro synthesis of
capped RNA followed by poly-A tailing (Ambion).
Mature dendritic cells (mDC) were generated from
plate adherent monocytes, as described.21,22
Generation of MHC cell library
To generate cell lines expressing single Mhc al-
leles, cDNA gene sequences of differentMhc alleles
were linked to reporter genes GFP or CFP via an
internal ribosomal entry site (IRES). Resulting
gene cassettes were molecularly cloned into the
c-retroviral vector MP71 for the generation of viral
particles.23 K562 cells in exponential growth phase
were incubated with viral supernatant in the pres-
ence of 4lg/mL of protamine sulfate (Sigma–
Aldrich) followed by 2h of spinoculation at 800 g and
32C. Transduced K562 cells were sorted upon
surface MHC expression using magnetic bead sep-
aration. To confirm expression of the target MHC
transgene cassette, RNA/cDNAwas generated after
several passages followed by polymerase chain re-
action (PCR) amplification of the transgene cassette
and Sanger sequencing. Resulting electrophero-
grams were analyzed to confirm single-target MHC
expression. To assess the gene sequence expressing
the exact epitope recognized by the E5 TCR, K562-
B*15:01 cells were transduced with truncated gene
segments (minigenes) of E5. To do so, HPV16 E5
reference sequences of different length were am-
plified byPCR, and resultingminigeneswere cloned
into the c-retroviral vectorMP71, whichwas used to
generate viral supernatant for transduction.
Identification of antigen–MHC-specific
T-cell responses
K562 cells of the MHC cell library were trans-
fected with 10lg of antigen ivtRNA ofHPV16 E5 or
CMV pp65 using electroporation. Four to six hours
after pulsing, K562 cells were harvested and co-
cultured with peripheral blood mononuclear cells
(PBMCs). Two assays were chosen to determine
antigen–MHC-specific reactivity of T cells within
PBMC samples. First, supernatants of co-cultures
were used to measure interferon (IFN)-c release by
enzyme-linked immunosorbent assay (ELISA; BD
Biosciences). Second, T cells were labeled with
antibodies to determine the expression of the T-cell
activation marker CD137 and co-stained for CD8.
The antigen–MHC specificity of T cells was re-
garded as positive when signals were detected in
both assays and showed elevated levels compared
to other antigen–MHC combinations.
Isolation of antigen-specific TCRs
Upon detection of specific T cells, PBMC samples
frozen after one stimulation cycle were thawed and
re-stimulated for 14 days to be used in a co-culture
assay only with E5-specific T cells (K562-B*15:01) or
pp65-specific T cells (K562-B*07:02). CD137- and
CD8-positive T cells (between 500 and 10,000) were
directly sorted in cell lysis buffer to purify whole-cell
RNA. For efficient analysis, it was necessary to in-
troduce an amplification step of TCRgene sequences.
Unknown TRAV and TRBV gene segments pre-
cluded them from classical PCR amplification.
Therefore, the SMARTerRACE cDNAamplification
kit (Clontech) was used, according to the manufac-
turer’s instructions. PCR products were separated
on a 1.5% agarose gel, and bands representing am-
plified TRA and TRB chains were excised and puri-
fied using the Invisorb Fragment CleanUp Kit
(Stratec). DNAwas eluted in 30lL of elution buffer.
Purified PCR fragments were used for ligation into
the pCR4Blunt-TOPO vector using the Zero Blunt
TOPOPCRCloningKit forSequencing (Invitrogen).
After ligation of the RACE PCR products into
the TOPO cloning vector, DNA preparations of the
vectors were used for further processing. Suitable
primers were designed (Eurofins Genomics), which
contained sequences complementary to flow cell oli-
gos, barcoding sequences, and binding sites for the
TOPO cloning vectors. Primers were used to amplify
TRAV and TRBV repertoires from the TOPO cloning
vectors, and resulting PCR products were used for
paired-end sequencing on a MiSeq machine (Illumi-
na). After filtering reads, which fulfilled quality cri-
teria (Eurofins), readswereclustered (>98%sequence
similarity) and assigned to sequence representatives
(Eurofins). TCR repertoire analysis was performed
usingweb-based IMGT/HighV-quest (www.imgt.org/
HighV-QUEST/).24,25 TCR chain clonotypes were
sorted upon frequency of clustered reads.
Wild type TRAV and TRBV sequences of TCR
chains,whichwere found to bedominantly expressed
in antigen-MHC-specific T cells, were fused to codon-
optimizedmurineTRACandTRBCregions, andeach
TRA and TRB gene was ligated separately into the
MP71 vector to enable combinatorial expression of
different TRA andTRB chains. After identification of
TRAandTRB chain pairs, which formed a functional
TCR,modifiedTCR transgene cassettes for improved
expression in primary human PBMCs were con-
structed as described.26,27 To increase transgenic
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TCR expression further, codon optimization was
performed (GeneArt).28
Generation of c-retroviral particles
Calcium phosphate transfection of HG820-GALV
packaging cells with MP71 plasmids (18lg) carry-
ing the Mhc or TCR transgene cassettes, respec-
tively, was used to generate virus particles. Viral
supernatant was harvested 48h after transfection
and used for transduction of K562 cells. For trans-
duction of PBMCs, viral supernatant was harvested
after 48h and used for the first transductions. Then,
freshmediumwas added to the packaging cells, and
after another 24h, the supernatant was harvested
and used for a second transduction.26,29
Transduction of PBMCs
PBMCs were isolated from blood samples of
healthy donors, with written informed consent
and approval of the Institutional Review Board of
the Max Delbru¨ck Center for Molecular Medicine
Berlin. To isolate PBMCs, 30mL of heparinized
blood was mixed with phosphate-buffered saline,
and gradient centrifugation was performed using
Biocoll separating solution (Millipore). PBMC
transduction was carried out as described.26
IFN-c release assays
Co-culture assays were performed to assess
antigen-specific reactivity of T cells to different sets
of target cells (K562-MHC, LCLs, and HPV16-
positive tumor cell lines). LCLs were pulsed with
HPV16 E5 ivtRNA using electroporation 4–6h be-
fore adding TCR-transduced T cells. GFP electro-
poration was performed in parallel to assess
transfection efficiency. HPV16-positive tumor cell
lines were pretreated with 100ng/mL of IFN-c
(Peprotech) for 24h before they were trypsinized,
washed extensively, and transfected with E5 ivtR-
NA. Tumor cell lines were seeded in plates for co-
culture for up to 6h prior to adding T cells. T cells
stimulated with PMA and ionomycin were used as
a positive control. To assess peptide specificity,
K562-MHC cells were pulsed with different pep-
tides (Biomatik) at a concentration of 10–6 M. To
do so, peptides were added to the cell suspension of
K562-MHC cells and TCR-transduced T cells. For
peptide titration assays, K562-HLA cells were
pulsed with different molar amounts of peptide,
and TCR-transduced T cells were added for an
overnight co-culture. The alanine scan was per-
formed, as described before, with minor changes.30
Nine peptides were used each having one amino
acid substitution to alanine at a different position.
Peptides were added at a concentration of 10–8 M
to the co-culture of K562-B*15:01 cells and TCR-
transduced T cells. IFN-c release of T cells was
determined as indication for antigen-specific TCR
engagement by ELISA.
Flow cytometry analysis
Surface expression of transgenic TCRs was de-
tected using an antibody directed against the mu-
rine constant TCR b region (mTRBC; Biolegend)
and flow cytometric analysis. Anti-CD8 and anti-
CD137 antibodies (Biolegend) were further used
for T-cell characterization. HLA-DR (MHC class
II), CD80, CD83, andCD86 for phenotyping ofmDCs
as well as the HLA-A,-B,-C antibody for measuring
surface MHC expression on K562-HLA cells were
purchased from Biolegend. Before antibody staining,
mDCs were incubated for 10min with a human Fc
blocking antibody. Sytox blue (Thermo Fisher Sci-
entific) was used for live/dead staining of cells, and
flow cytometry measurements were performed at a
MACSQuant (Miltenyi). Fluorescence-activated cell
sorting (FACS) was performed on an Aria II (BD).
RESULTS
T-cell expansion on antigen-expressing DCs
T-cell responses were investigated to the HPV16
oncogene E5,31 which is a potential target for im-
munotherapy of HPV-associated malignancies such
as cervical as well as head and neck cancers. To date,
isolation of E5-specific TCRs has not been reported.32
E5 was found to be frequently expressed at the RNA
and protein levels in HPV-induced tumors.33,34 Epi-
tope prediction for E5 revealed 61 epitopes as po-
tential binders to at least one of the sixMHCalleles of
the PBMC donor used in this study (Supplementary
Table S1; Supplementary Data are available online
at www.liebertpub.com/hum). In addition to E5, the
highly immunogenic antigen pp65 of CMV was
used.35 Two hundred epitopes of pp65 were pre-
dicted to bind with high or intermediate affinity
to one of the six donor MHCs (Supplementary
Table S2). In principle, each of these epitopes of
HPV16 E5 and CMV pp65 in combination with
its cognate MHC could generate a target for TCR-
mediated T-cell attack. In reality, however, the
numbers of dominant T-cell clonotypes responding
to antigenic epitopes is much lower and not possible
to predict with currently available algorithms.
To identifyT-cell clonotypes responding toE5and
pp65, mDCs expressing MHC II, CD80, CD86, and
the differentiation marker CD83, were prepared
from plate-adherent monocytes (Supplementary
Fig. S1A). mDCs were transfected with ivtRNA
of the antigens to ensure endogenous processing
and MHC presentation22,36 (Fig. 1A). Transfection
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efficiency was >90%, as measured by GFP ivtRNA
expression (Supplementary Fig. S1B). Autologous
PBMCs were stimulated twice for 14 days with
antigen-expressing mDCs to induce proliferation of
antigen-specific T-cell clones.
Detection of T-cell responses using the MHC
cell library
To decipher antigen-specific T-cell responses,
an MHC cell library was generated consisting of
K562 cell lines expressing single MHC alleles.
MHC gene sequences were stably transduced in
K562 cells, which were then sorted for homoge-
nous MHC surface expression. The MHC cell li-
brary, comprised of K562 cells expressing >40
different MHC alleles, provided the cellular re-
agents representing each of the six MHC I alleles
of the study donor (Fig. 2A). E5-expanded donor
T cells were co-cultured individually with each of
the six different MHC-expressing K562 cell
lines that were additionally transfected to each
express one of the two study antigens. Expression
of CD137 activation marker of CD8-positive T
cells (Supplementary Fig. S2) and cytokine se-
cretion of IFN-c upon stimulation were correlated
to forma concise picture of T-cell responses (Figs. 1B
and 2B). T cells showed clear recognition of E5-
expressing K562-B*15:01 cells, while no reactivity
to any other E5-MHC combination was observed.
PBMCs enriched for CMV contained T cells solely
specific for pp65 in combination with B*07:02
(Figs. 1B and 2B). T-cell donors seropositive
for CMV were described to have very high pre-
cursor frequencies of pp65-specific T cells37 and
although 200 possible pp65-specific pMHC com-
binations were calculated, T cells targeting pMHCs
other than B*07:02 were not detected. This indi-
cated that pp65-B*07:02 was also an immuno-
dominant TCR target.38
TCR gene sequence analysis
To analyze the TCR repertoire of responding
T cells (Fig. 1C), CD137-expressing T cells were
sorted on a FACS (Supplementary Fig. S3) and
directly used to extract RNA and to clone TCR-
specific cDNA into the TOPO vector. PCR products
of vector preparations were used for paired-end
deep sequencing to analyze variable TCRa (TRAV)
and TCRb (TRBV) gene segments, respectively.
The quantity of reads of a specific TRAV or TRBV
clonotype was indicative for the frequency of a
T-cell clonotype within the sorted T-cell popula-
tion. In all samples, a strong enrichment for very
few chains was observed (Fig. 2C–F), showing that
pMHC-triggered CD137 activation was a selective
process involving only a few T-cell clonotypes.
Figure 1. Multi-step approach for the identification, isolation, and re-expression of peptide major histocompatibility complex (pMHC)-specific T-cell receptors
(TCRs). (A) Dendritic cells (DCs) were transfected with full-length antigen-encoding, in vitro-transcribed (ivt) RNA to enable natural processing and pre-
sentation of MHC I epitopes. Antigen-expressing DCs were used to trigger pMHC-specific T-cell responses. (B) An MHC I cell library consisting of K562 cells
expressing single MHC alleles was generated to identify T-cell responses with regard to each MHC. (C) pMHC-specific T cells were enriched using
fluorescence-activated cell sorting (FACS), and TCR gene sequence analysis was performed to identify predominant TCRa and b chains by next-generation
sequencing. (D) Functional TCRs were generated by re-expressing predominant TCRa and b chains via retrovirus vectors in primary T cells. (E) TCR-
transduced T cells were used to map the unknown epitope and (F) to characterize TCR functionality with regard to antigen and tumor cell line recognition. TCR-
td, T cell receptor-transduced.
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T cells responding toHPV16E5 in combinationwith
B*15:01 revealed four TRAV chains that appeared
at a frequency of >10% of all reads (Fig. 2C). In the
TRBV repertoire, six chains yielded a frequency of
>5% and were chosen for further analysis (Fig. 2D).
TCR gene sequence analysis of pp65-B*07:02-
reactive T cells exhibited one dominant TRAV chain
contributing to >80%of total reads (Fig. 2E) and two
predominant TRBV chains (Fig. 2F).
Re-expression of functional TCRs
Next, single-chain TRA and TRB retroviral
vectors containing predominant chains for combi-
natorial re-expression in primary T cells were
generated to identify TRA and TRB chains forming
functional, antigen-specific TCRs (Fig. 1D). Con-
stant TRA (TRAC) and TRB (TRBC) gene segments
were exchanged by murine codon-optimized coun-
terparts to enhance TCR expression (Fig. 3A).26–28
Thus, surface expression of all TRA/TRB combi-
nations became detectable using a monoclonal an-
tibody directed against the murine TRBC chain
(Fig. 3B and C). Four TRA chains and six TRB
chains derived from E5-B*15:01-specific T cells
were re-expressed in 24 different combinations in
primary T cells. TCR surface expression on CD8-
positive T cells was achieved for every combination
at rates between 6.7% and 27.1% (Fig. 3B). There-
fore, all 24 TCRs were available for testing antigen
specificity for E5-B*15:01. Also, both TRA/TRB
combinations from the predominant TCR chains
found in pp65-specific T cells were expressed at the
cell surface and used for testing the antigen speci-
ficity to pp65-B*07:02 (Fig. 3C). Strikingly, for
E5, there was only one TRAV/TRBV combination,
where T cells showed clear recognition of K562-
B*15:01 cells while exhibiting no reactivity to target
cells without E5 antigen (Fig. 3D). None of the other
23 TRA/TRB combinations provided T cells with
antigen specificity that led to elevated levels of
IFN-c release. For pp65, one TRAV/TRBV combi-
nation formed a functional, antigen-specific TCR,
leading to specific IFN-c release of T cells upon en-
counter of K562-B*07:02 cells expressing pp65
(Fig. 3E). Expression of the second TRA/TRB com-
bination completely abrogated cytokine release,
demonstrating that only correct pairs of TRA and
TRB chains led to selective pMHC specificity.
To enable reproducibly high TCR transduction
rates of primary T cells, TCR transgene cassettes
were further optimized by linking TRB genes via
a P2A element with TRA genes in the retroviral
Figure 2. Detection of T-cell responses using an MHC cell library and TCR gene sequence analysis. (A) Flow cytometric analysis of surface HLA allele
expression of K562 cells stably transduced to express single MHCs. Gray, tinted area indicates K562 cells without transgenic MHC expression. Black line
shows shift in MHC expression upon stable transfection. (B) T cells expanded on antigen (HPV16 E5, CMV pp65)-expressing DCs were co-cultured with
antigen-expressing K562 cells of the MHC cell library. The upper panel shows surface expression of CD137 on T cells detected by flow cytometry. The lower
panel shows interferon (IFN)-c release of T cells into the supernatant measured by enzyme-linked immunosorbent assay (ELISA). (C and D) HPV16 E5-B*15:01-
and (E and F) CMV pp65-B*07:02-specific T cells used for TCR gene analysis by next-generation sequencing. Indicated are percentages of total reads assigned
to each sequence cluster, which has a sequence representative indicated on the x-axis. Cluster representatives were analyzed using IMGT/HighV-Quest.
Depicted are (C and E) TRAV and (D and F) TRBV gene segments of each cluster representative. An arbitrary cutoff was set at 5% or 10%, respectively. TCR
chains above the cutoff were used for further analysis.
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vector MP71 and applying codon optimization (Sup-
plementary Fig. S4A).26,27 Retroviral transduction
of primary T cells with optimized TCR transgene
cassettes yielded overall TCR transduction rates of
around 40% (Supplementary Fig. S4B), and T cells
were functional, as they specifically recognized E5-
B*15:01- and pp65-B*07:02-expressing K562 cells
(Supplementary Fig. S4C). T cells transduced with
optimized TCR transgene cassettes were used for all
subsequent experiments.
Epitope mapping
Functional TCRs were selected for recognition of
immunodominant pMHC combinations without
prior knowledge of epitope specificity. To map the
exact epitope sequence recognized by the E5 TCR
(Fig. 1E), 3¢-truncated minigenes of the E5 onco-
gene were expressed in K562-B*15:01 cells using
MP71 retroviral vectors. Additionally, a codon-
optimized variant of E5 was used to test if the
target epitope was expressed from an alternative
reading frame (Fig. 4A).39 T cells transduced with
the optimized E5 TCR recognized target cells car-
rying the 189nt short minigene of E5, but did not
recognize target cells expressingminigenes shorter
than 126nt (Fig. 4A). Thus, the E5 TCR was spe-
cific for an epitope translated from the 126–189nt
coding region of E5, corresponding to the amino
Figure 3. Re-expression of TCR chains in peripheral blood lymphocytes and analysis of TCR function. (A) Map of TRA and TRB chain genes molecularly
cloned into the c-retrovirus vector MP71. Human TRAV and TRBV gene segments were fused to murine TRAC and TRBC gene sequences. Flow cytometry plots
of primary T cells transduced with different TRA/TRB combinations found in (B) E5-B*15:01- and (C) pp65-B*07:02-specific T cells are shown. Numbers in the
upper right corner indicate percentages of expression of murine TRBC chains in CD8+ T cells. T cells transduced with different TRA/TRB combinations were co-
cultured for 18 h with (D) K562-B*15:01 target cells expressing HPV16 E5 or no antigen and with (E) K562-B*07:02 target cells expressing CMV pp65 or no
antigen. Shown is IFN-c release of T cells measured by ELISA.
1164 LORENZ ET AL.
acid (aa) sequence 42–63. NetMHCpan3.0-based
online binding prediction of all possible 9-mer and
10-mer peptides from the E5 oncoprotein returned
six epitopes as potential binders to B*15:01 in the
aa stretch 42–63 (Table 1). The top three predicted
peptides of this aa stretch were used to pulse K562-
B*15:01 target cells (Fig. 4B). E5 TCR-transduced
T cells did not recognize target cells pulsed with
the LLWITAASAF peptide and un-pulsed target
cells, while releasing high amounts of cytokine
upon encounter with target cells displaying the
SAFRCFIVY (SAF) 9-mer and its corresponding
5¢-elongated ASAFRCFIVY (ASAF)10-mer epitope
(Fig. 4B). Thus, the E5 TCR specifically recognized
the minimal-required SAF 9-mer epitope presented
by B*15:01, revealing a previously unknown im-
munogenicHPV16 target for T cells. For pp65, it had
been described that the TPRVTGGGAM (TPRV)
epitope presented by B*07:02 is a frequent target
for pp65-specific T cells.40 To assess if this epitope
was also the target for the pp65 TCR, K562-B*07:02
cells were pulsed with this TPRV 10-mer epitope
(Fig. 4B) and co-culturedwith pp65TCR-transduced
T cells. Indeed, high amounts of IFN-c release con-
firmed that the TCR was specific for the TPRV epi-
tope and that the approach yielded a functional TCR
specific for an immunodominant pMHC combina-
tion (Fig. 4B).
Preclinical TCR characterization
The E5 TCR was assessed for its pMHC peptide
sensitivity as a reflection of TCR affinity (Fig. 1F).
Figure 4. Epitope mapping and TCR characterization (A) 3¢-truncated minigenes of E5 (wt) and a codon-optimized (co) variant of E5 were constructed and
stably expressed in K562-B*15:01 cells. E5-TCR-transduced and untransduced primary T cells were co-cultured with antigen-expressing K562-B*15:01 cells,
and IFN-c release was measured by ELISA. (B) Peptides from the E5 amino acid sequence 42–63 predicted to bind to B*15:01 as well as the TPRV peptide from
pp65 are depicted. E5-TCR- and pp65-TCR-transduced T cells as well as untransduced T cells were co-cultured with antigen-expressing K562-B*15:01 and
-B*07:02 cells, respectively, and reactivity was measured by IFN-c release in ELISA. (C) E5-TCR-transduced and untransduced T cells were co-cultured with
titrated amounts of SAFRCFIVY peptide on K562-B*15:01 cells. Indicated are molar (M) peptide concentrations. Reactivity was assessed by IFN-c ELISA. (D)
Alanine scan. Nine different peptides were generated, each with an alanine substitution in one position. Peptides were loaded at a concentration of 10–8 M on
K562-B*15:01 cells, and IFN-c release of E5-TCR-transduced T cells was measured by ELISA. (E) Cervical (CaSki, SiHa) and head and neck (SCC090, SCC152)
cancer cell lines, which do not express E5, were pretreated with IFN-c or transfected with E5 RNA. To test their capacity for producing the SAFRCFIVY epitope,
E5-TCR-transduced and untransduced T cells were analyzed for recognition of the cell lines. IFN-c release was measured by ELISA.
Table 1. HPV16 E5 binding prediction to HLA-B*15:01
Position Peptide nM Rank Binding level
47 LLWITAASAF 8.71 0.01 SB
71 FLIHTHARF 20.18 0.09 SB
70 LFLIHTHARF 57.00 0.40 SB
29 RPLLLSVSTY 78.53 0.60 WB
54 SAFRCFIVY 90.62 0.60 WB
53 ASAFRCFIVY 118.68 0.80 WB
50 ITAASAFRCF 146.56 0.90 WB
32 LLSVSTYTSL 196.44 1.10 WB
51 TAASAFRCF 196.54 1.10 WB
33 LSVSTYTSL 214.45 1.20 WB
62 YIIFVYIPLF 219.33 1.20 WB
5 TASTTLLACF 220.30 1.20 WB
6 ASTTLLACF 327.09 1.60 WB
10 LLACFLLCF 338.47 1.70 WB
48 LWITAASAF 400.48 1.80 WB
71 FLIHTHARFL 432.66 1.90 WB
nM, nanomolar affinity of peptide to MHC; rank, percentage rank
compared to training database of 180,000 peptides; SB, strong binder; WB
weak binder; bold, epitope recognized by E5-TCR.
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Optimal affinity is a key characteristic of a useful
TCR, which, upon expression in T cells, contributes
to overall T-cell avidity that in turn impacts on
clinical efficacy. Very high affinities/avidities con-
tributed to off-target toxicities in clinical trials,41,42
whereas lower affinities/avidities reduced efficacy
of TCR immunotherapy. E5 TCR affinity to pMHC
was measured in a peptide titration assay. TCR-
transduced T cells recognized K562-B*15:01 target
cells at peptide concentrations as low as 10–9 M.
Half maximum IFN-c release was determined
between 10–8 and 10–9 M, indicating a naturally
high TCR affinity to pMHC43 (Fig. 4C). Although
no results indicated potential cross- or background
reactivity of the E5 TCR, we investigated whether
sequences in the human proteome might be po-
tential off-targets. To identify the aa of SAF es-
sential for TCR recognition or MHC binding, an
alanine scan was performed, whereby each aa of
the SAF epitope was substituted by alanine (A).
Residues at positions p2 (already A), p3 (F), p7 (I),
and p8 (V) could be replaced by alanine without
fully abrogating TCR-mediated antigen recogni-
tion (Fig. 4D). The Expitope online webtool19 was
used to find epitopes in the human proteome
similar to SafRCFivY, where lowercase positions
were allowed to be replaced by any aa. The Ex-
pitope algorithm found two epitopes with five of
nine fixed aa shared with SAF. Both epitopes had
very low overall expression scores in human tis-
sues and very low MHC binding affinities to
B*15:01, which most likely excludes them as po-
tential off-targets for the E5 TCR (Supplementary
Table S3).
The screening for antigen-specific T cells relied
on the antigen-processing capacity of K562 cells. To
exclude that the SAF epitope could only be artifi-
cially generated by K562 cells, a panel of B*15:01-
positive LCLs was transfected with the E5 antigen
and analyzed for recognition by E5 TCR-transduced
T cells. Supplementary Figure S5 shows that all
LCLs were recognized, while B*15:01-negative
LCLs were ignored. Since the LCLs were derived
from unrelated donors, the results also indicate
that the SAF epitope was readily processed by
cells of different genotypic origin.
HPV16 E5 is involved in early tumorigenesis,44
whichmay explain why established tumor cell lines
naturally expressing HPV16 E5 are not available.
As an alternative, to analyze if HPV16-positive
patient-derived cervical and head and neck cancer
cell lines have capacity to process and present SAF
naturally, they were transfected with E5 ivtRNA
and B*15:01 ivtRNA, as all cells were negative for
this allele. Figure 4E shows that cell lines CaSki,
SiHa, SCC090, and SCC152 could each efficiently
process and present the SAF epitope on B*15:01,
thereby inducing IFN-c release by E5 TCR-
transduced T cells.
DISCUSSION
Compared to the vast number of polypeptide
sequences in a cell’s proteome, only a small pro-
portion of epitopes (1,000–10,000) is presented
on the estimated 100,000 MHCs at the cell sur-
face,45,46 and presumably most epitopes are de-
rived from self-proteins. Degradation of an antigen,
TAP transport, peptide trimming, and binding af-
finity to the six available MHCs alleles influence
the formation of immunogenic pMHC complexes
eligible for T-cell attack. Reliable prediction pro-
grams for these different complex processing steps
are lacking, andMHC binding prediction programs
are less well trained on non-HLA-A*02:01 alleles.
Considering all possible pMHC combinations that
can be formed from one antigen sequence and six
different MHCs, it remains a challenge to deter-
mine which pMHC(s) are finally adequately ex-
pressed and able to trigger TCR-dependent T-cell
activation.
In general, several approaches are available to
generate antigen-specific T cells and to isolate the
respective TCRs for immunotherapy. First, allo-
geneic priming can be employed to obtain allo-
restricted antigen-specific T cells.9 A challenge in
this approach is the separation of tumor antigen-
specific T cells from those recognizing the allo-
MHC, irrespective of the presented peptide. Sec-
ond, T cells can be isolated frommice that recognize
human target proteins. However, human T cells,
which are genetically engineered with murine
TCRs, may not persist in humans and may become
a target for cytotoxic T cells or antibodies, as re-
cently shown.47 Third, a transgenic mouse carrying
the full human TCR repertoire can be used to gen-
erate high-affinity TCRs. Here, the antigenic pep-
tide that is used for immunization of the mouse has
to differ from the murine counterpart in its amino
acid sequence to induce an immune response.48
Unfortunately, at present, this elegant approach is
not available for other HLA alleles than HLA-
A*02:01.
Here, a platform approach is presented that
enables detection, isolation, and characterization
of antigen-specific TCRs in the absence of pre-
determined target epitope and MHC binding in-
formation, instead allowing APC function to reveal
the best-suited antigenic pMHC(s) for surface ex-
pression. The isolation of the E5 TCR specific for
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the SAF/B*15:01 pMHC showed the potential of
this platform approach to identify a TCR specific
for a previously unknown viral target pMHC. Se-
venteen epitopes other than SAF were also ranked
in the best 0.6% of peptides predicted to bind to the
six studyMHCs compared to the training database
of netMHCpan3.0 (Supplementary Table S1), but
only SAF was found to stimulate T cells as an im-
munodominant epitope. Interestingly, the strategy
described here would also enable detection of T-cell
responses to proteasome-spliced epitopes—a class
of epitopes that cannot be predicted by currently
available algorithms.49,50
This platform can be used to identify novel
pMHC combinations as therapeutic targets for
TCR immunotherapy. The authors are currently
also developing anMHC II cell library to enable the
identification of novel MHC II epitopes as targets
for CD4-based TCR immunotherapy.
In the future, optimal personalized TCR im-
munotherapies will require the means to generate
sets of TCRs targeting different pMHCs that are ef-
ficiently expressed on the surface of cancer cells. Pa-
tients for TCR immunotherapy can then be grouped
according to MHC expression, allowing enlargement
of patient groups eligible for treatment.
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